Fresenius Medical Care AG & Co. (FMS)
(Delayed Data from NYSE)
$20.10 USD
-0.11 (-0.54%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $20.11 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
Price, Consensus and EPS Surprise
FMS 20.10 -0.11(-0.54%)
Will FMS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for FMS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for FMS
Comfort Systems USA and Boeing have been highlighted as Zacks Bull and Bear of the Day
3 Medical Device Stocks With Solid Dividend Yield: CAH & Others
FMS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now
Inogen (INGN) Up 26.6% Since Last Earnings Report: Can It Continue?
Paragon 28, Inc. (FNA) Moves 16.2% Higher: Will This Strength Last?
Other News for FMS
GLOBAL BROKER RATINGS: Stifel cuts Caterpillar; HSBC likes Ashtead
March's Dividend Portfolio Update Sets New All-Time Record - 100 Holdings, 21 Buys
Doctors perform first combined heart pump and pig kidney transplant surgery
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
FMS Crosses Above Key Moving Average Level